Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Conditions

Rhabdomyosarcoma

What is the purpose of this trial?

This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with radiation therapy in treating patients with rhabdomyosarcoma.



Participation Guidelines

Age:
Up to 49 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Children's Oncology Group
National Cancer Institute (NCI)
Dates:
December 2006
Last Updated:
February 26, 2014
Study HIC#:
1008007246

Clinicaltrials.gov ID: NCT00354835